HPS masthead
What's New?
. Fukushima Decontamination Report
. CRCPD & CDC Grants for Volunteer Corps
. America's Nuclear Future
. February Newsletter
. Boice Nominated President of NCRP
. February Journal
. February ORS
. Schauer Given the Butterfly Award from Image Gently
. Kase President's Report to IRPA
. IRPA13 Accepting Posters
Upcoming Events
. HPS Midyear - Issues in Waste Management
5-8 February 2012
Dallas, Texas
. NRC Regulatory Information Conference
NRC Regulatory Information Conference
13-15 March 2012
Rockville, Maryland
. NCRP Annual Meeting
12-13 March 2012
Washington, DC
. James E. Turner Memorial Symposium
Call for Abstracts
18-19 April 2012
Oak Ridge Associated Universities, Pollard Auditorium, Oak Ridge, Tennessee
. IRPA13
13-18 May 2012
Glasgow, Scotland
. Canadian Radiation Protection Association (CRPA) Annual Meeting
27-30 May 2012
Halifax, Nova Scotia
. ACS Undergrad Summer Schools
10 June- 20 July 2012
. Nuclear Regulatory Commission Meeting Webcasts
February 2012
Bethesda, Maryland
09 February 2012

Technical Justification for Using the Presence of Cs-137 Identified in Whole Body Counts as a Flag for Undertaking In Vitro Analysis of Sr-90/Y-90 at the INL

S. McCord1; B. Anderson2; P. Ruhter2; and R.R. Brey1 (1Idaho State University - Dept. of Physics/Health Physics Program; 2Idaho National Laboratory)

It has been argued that if the ratio of Sr-90/Y-90 to Cs-137 in contamination is well characterized and less than 5 to 1, then Sr-90/Y-90 urine analysis need not be performed except if Cs-137 is detected during a whole body count. The argument is based upon three assertions: 1. Experience has indicated that rarely, if ever, has there been an uptake of strictly Sr-90/Y-90 in the absence of Cs-137 at the INL. 2. The composition of radioactive contamination at most of the INL facilities is best described as mixtures of different radionuclides varying as a function of the chemical and physical processes inherit at each facility. 2. Ratios of the various radionuclides comprising the radioactive contamination at the INL facilities may be well characterized. With a 2.0-nCi 137Cs MDA, and limiting protocol application to a less than 10 to 1 ratio, there would not be an opportunity to miss a significant (> 100 mrem CEDE) Sr-90/Y-90 exposure even if the bioassay occurred 1-year post bolus intake. We verify these assertions and conclude that the protocol is technically justified. Cs-137 may serve as an indicator of Sr-90/Y-90 contamination if bioassays are performed within 20 days of intake.

Return to Session list.

image
image
Home Affiliates Ask the Experts Radiation Terms Employment Meetings